Trial Profile
A phase I, open-label, single-dose, crossover study to evaluate the relative bioavailability (rBA) and effect of food on New Pediatric Formulation of Idelalisib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Waldenstrom's macroglobulinaemia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Gilead Sciences
- 29 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics